Related references
Note: Only part of the references are listed.Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
Chronic Myeloid Leukemia: Reversing the Chronic Phase
John M. Goldman
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Michele Baccarani et al.
BLOOD (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia
Dong Hwan (Dennis) Kim et al.
CANCER (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
Sebastian Kreil et al.
BLOOD (2007)
Home-brew FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia
Francesco Albano et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
A Quintas-Cardama et al.
BLOOD (2005)
Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia
Y Yoong et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions
BJP Huntly et al.
BLOOD (2003)
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia
BJP Huntly et al.
BLOOD (2003)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
VHJ van der Velden et al.
LEUKEMIA (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients
CT Storlazzi et al.
GENES CHROMOSOMES & CANCER (2002)
Derivative chromosome 9 deletions in chronic myeloid leukemia:: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability
BJP Huntly et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia
J de la Fuente et al.
BLOOD (2001)
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
BJP Huntly et al.
BLOOD (2001)
Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:: expression profiling, resistance to interferon therapy, and poor prognosis
N Cohen et al.
CANCER GENETICS AND CYTOGENETICS (2001)
Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis
E Kolomietz et al.
BLOOD (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Deletion of the 5′-ABL region:: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients
C Herens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
